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ABSTRACT 
Background: Lack of appointment compliance is a problem that is consistent throughout 
outpatient clinics. Research has found that personal phone calls as opposed to automated systems 
can improve appointment compliance. Another barrier that has been identified is the frequency of 
appointments. For individuals with sickle cell disease, attending appointments is important for 
managing their medications and multi-disciplinary care. In this study, we seek to determine 
whether 2 standard of care changes have impacted the no show rate in a sickle cell clinic based at 
Children’s Hospital of Pittsburgh of UPMC (CHP).  
Methods: Clinical data were reviewed to assess the impact of these changes on the no-
show rate before and after these changes were made.  Statistical analysis was performed utilizing 
paired analysis and summary statistics. All patients who were followed in clinic at CHP both 
during a set time period before and after implementation and met inclusion criteria were included 
in the assessment. 
Results: Changes to the appointment frequency for hydroxyurea patients and the personal 
reminder phone calls did not statistically significantly change the no-show rate with a p-value 
0.6818 and 0.3421, respectively. There were 67 patients included in the hydroxyurea appointment 
frequency and 101 included in the phone call reminder portion.  
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Conclusions: Reducing the frequency of appointments in the subset of patients taking 
hydroxyurea and phone call reminders did not increase appointment compliance, but further 
research needs to be conducted to determine the full impact of these interventions. Methods to 
increase appointment compliance are especially important in the sickle cell disease population, as 
attending appointments is how medications and preventative and symptomatic care are managed. 
Further research needs to be done on barriers to access to understand why patients are not attending 
appointments before new implementations can be made.  
Public Health Significance: Appointment compliance is important for keeping 
individuals healthy through preventative measures, following up with a chronic condition, and 
making the best use of health care resources.  
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1.0  INTRODUCTION 
Appointment compliance is beneficial to healthcare providers and hospital systems, but 
most importantly it is beneficial to the patients. Patients who are not attending their appointments 
are reducing the quality of care they can receive. For patients with sickle cell disease, appointment 
compliance is important to manage medications, check up on the patient and educate families, 
which are established preventative measures for sickle cell complications and painful crises.1 
There are approximately 100,000 people nationwide who are living with sickle cell disease, 
making it one of the most common inherited genetic diseases. Primarily African Americans are 
affected, and the disease affects about 1 in 365 African-American individuals.2 There have been 
many significant improvements in the management of this condition, which has increased the 
lifespan from approximately 20 years to about 42-48 years of age for individuals with HbSS.3 
Attending appointments, and in turn receiving the care that they need plays a critical role in the 
well-being of these patients.4 
Standard of care changes initiated by the sickle cell team at the Pediatric Sickle Cell Clinic 
at Children’s Hospital of Pittsburgh to increase appointment compliance have included personal 
reminder phone calls and increasing the interval between appointments for hydroxyurea follow-
up. In other clinics, it proved effective to have personal phone calls as opposed to the automated 
system. Thus it was decided that personal calls would be conducted in addition to the automated 
system.5,6,7 The frequency of appointments has also been identified as a barrier for 
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individuals8;therefore, the clinic decided to increase the interval between appointments when 
medically feasible. Additional data for the use of hydroxyurea in the pediatric population has 
permitted the option of a longer interval between clinic visits for children with sickle cell disease 
on a stable dose of hydroxyurea with no evidence for toxicity.  This provided an opportunity to 
change the frequency of clinic visits in a subset of patients on hydroxyurea.  This study will provide 
the information necessary moving forward to see if in this particular clinic, the Pediatric Sickle 
Cell Clinic at Children’s Hospital of Pittsburgh, could continue to benefit from these changes. 
Furthermore, this study should provide insight about possible further implementations to the 
standard of care practices that will optimize compliance with clinic appointments. 
The goal of this study is to evaluate the effectiveness of changes to standard care to see if 
they increase appointment compliance in the Pediatric Sickle Cell Clinic. We hypothesize that 
multiple personalized reminders and reducing the frequency of appointments will increase the 
number of people attending clinic visits. This study will enable the research team to identify 
whether either of these two standard-of-care changes increases the percentage of families attending 
clinic and, furthermore, identify any additional barriers to appropriately adjust standard of care 
changes in the future.  
To address the appointment no-show rate in the Pediatric Sickle Cell Clinic at Children’s 
Hospital of Pittsburgh, the specific aims of this study are: 
• Assess the impact of increasing time interval between appointments on the no-show rate 
in the Pediatric Sickle Cell Clinic for Hydroxyurea follow up patients. 
• Assess the impact of reminding patients of their appointments on the no-show rate in the 
Pediatric Sickle Cell Clinic. 
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• Identify additional barriers that may reduce the no-show rate in the Pediatric Sickle Cell 
Clinic in the future.  
This evaluation of the current practices in the Pediatric Sickle Cell Clinic will provide 
results that give information about how effective current practices are, but also give insight into 
some barriers to appointment compliance that could be addressed in future standard of care 
implementations. Study results will identify the efficacy of such practices and whether it makes 
sense to continue the practice moving forward. Increasing appointment compliance will not only 
help the patients receive the care they need and deserve, but will also help the healthcare 
professionals to see more patients. The cost of a no-show in a clinic can negatively impact the 
clinic by not using its resources as beneficially as possible. 
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2.0  LITERATURE REVIEW 
2.1 OVERVIEW OF SICKLE CELL DISEASE 
Sickle cell disease (SCD) is an inherited blood disorder, or hemoglobinopathy, that was 
first reported in 1910 by Dr. James Herrick who initially described the red blood cells as “peculiar 
elongated and sickle-shaped”9. The discovery of the condition was made in a student attending a 
professional school in Chicago who was from Grenada, West Indies and had struggled with 
anemia, presented with yellow sclera, and with a condition that was called muscular rheumatism.9  
 SCD is a condition that affects approximately 119,100 individuals in the United States 
and about 1 in 365 African Americans.2 It is one of the most common single gene disorders 
worldwide.2 The single gene mutation in HBB, Glu6Val, causes a normal hemoglobin (Hb A) to 
change to a sickled hemoglobin (Hb S). The altered hemoglobin is hard and sticky, which is what 
causes symptoms to present in those affected. Hb SS accounts for about 60-70% of sickle cell 
disease worldwide, however there are other common variants including Hb SC (16.1%), Hb Sβ+-
thalassemia and Hb Sβ°-thalassemia (3.2%).10 Other more rare variants exist such as Hb SD-
Punjab, Hb, SO-Arab, and Hb SE.  
Hallmarks of the disease include pain and vaso-occlusive crises, which include acute chest 
syndrome, infection, splenic sequestration, and cerebrovascular events.11 The variability of these 
clinical manifestations is multifactorial including genetic variation, level of fetal hemoglobin, 
inflammation, oxidative stress, and hypoxia-induced angiogenesis.12 
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2.1.1 History 
At the time of the original 1910 case report by Dr. James Herrick, no specific conclusions 
were drawn and no name was given to the condition.9 There was some time between Herrick’s 
first description and the mid-twentieth century when serious developments were made in the 
understanding of sickle cell disease. It was not until 1949, when Linus Pauling et al. had described 
sickle cell anemia as the first molecular disease, that it was suggested that sickle cell disease was 
a disease caused by the crystallization of the hemoglobin molecule13.   
Sickle cell disease had been described, and there were subsequent papers that attempted to 
identify the mechanism behind the disease. In 1949, electrophoresis revealed that sickle 
hemoglobin moved at a different rate than normal hemoglobin, which gave the indication that there 
was a molecular charge or shape difference.13 Electrophoresis was new at that time, so it wasn’t 
until 1954, when it was more widely available, that it was discovered that there were different 
forms of sickle cell disease, specifically Hb SC, which opened the door for the detection of other 
sickle cell disease variants.14 
One of the major findings occurred in 1958, when Ingram et al. used fingerprinting and 
tryptic digests to identify that there was a single amino acid change between the Hb A peptide and 
the Hb S peptide that resulted from the trypsin digestion. Both of these peptides contained the same 
nine amino acids, with the exception of the first glutamic acid of Hb A being changed in Hb S to 
a valine (EÆV).15,16 This was an important discovery for the future of understanding the 
mechanism for sickle cell disease, because it had validated the previously explained two less 
carboxyl groups in Hb S than in Hb A.13,17 This discovery also opened the door for further research 
into the mechanisms that cause sickling of the red blood cells.  
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Although the condition was discovered in the early 1900s and additional discoveries were 
made in the mid-1900s about how the HbS hemoglobin was abnormal, it was not until the 1970s 
when sickle cell disease awareness became a public concern. In 1971, there were fifteen 
community sickle cell organizations that came together for a conference, forming the National 
Association for Sickle Cell Disease.18 This organization remains today, but was renamed in 1994 
as the Sickle Cell Disease Association of America.18 Health organizations became involved and 
acted as advocates for research funding. In 1972, President Richard Nixon passed the National 
Sickle Cell Disease Control Act, which provided the establishment of voluntary sickle cell disease 
screening, education, information, testing, counseling, research, and treatment programs.19 Shortly 
after, between 1972-1973, the National Sickle Cell Disease Program was established and the 
National Heart and Lung Institute began funding comprehensive sickle cell centers, as well as 
creating a sickle cell branch.20 The research, promoted by funding from the National Heart, Lung, 
and Blood Institute (NHLBI) provided mechanisms for supporting research and disseminating 
information that led to important advancements for the medical care, survival, and quality of life 
for individuals with sickle cell disease. These advancements included newborn screening, 
penicillin therapy, pneumococcal vaccines, splenic palpation in splenic sequestration, hydroxyurea 
therapy, and bone marrow transplantation.21 
More recently, in 2006, another public health improvement for sickle cell disease occurred 
with the recommendation that sickle cell disease be added to all state newborn screening panels. 
However, many states were already screening for it by this time, based on the recommendation in 
1987 following the landmark study that showed that penicillin therapy beginning shortly after birth 
prevented deaths in infants and young children with sickle cell disease.22 New York was the first 
state newborn screening program that made sickle cell disease a required condition, having done 
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so since April 1, 1975.23 This has proved instrumental in early diagnoses and proper prevention of 
sickle cell related complications in the infant period.24 Before this was the case, many parents were 
unaware of their child’s condition and had to watch them suffer through infection, stroke, and 
frequently, death. It was possible for parents to be unaware of the condition because the symptoms 
of sickle cell disease are not present immediately after birth. The reason for no symptoms is 
because babies are typically born with fetal hemoglobin (HbF) as the primary hemoglobin, which 
persists at high levels until about the sixth month.25 Although very small amounts of HbF persist 
into adulthood, levels are reduced to about 0.6%.25 However, this can range between 0.3% to 4.4% 
in the normal adult population.26 Fetal hemoglobin is important because the sickle cell change 
affects the beta chains, and HbF is formed from alpha and gamma chains rather than beta chains.  
In 1988, a study was done on the effect of mortality of children with sickle cell disease. 
There were two groups in this study, one was a group whose disease status was detected in the 
newborn period containing 89 patients, the other was a group in which disease status was detected 
only after symptoms were present containing 64 patients. Mortality among the newborn screen 
group was 1.8% compared to 8% in the control group. That difference supports a significant 
change in life-threatening events for children with sickle cell disease.27 The justification for adding 
sickle cell disease was due to studies showing the benefit of early penicillin prophylaxis and the 
benefits it had on the survival of young children with sickle cell disease.22,28 The guidelines for 
management in conjunction with those that should be added to the newborn screen has solidified 
the testing of sickle cell disease and other related hemoglobinopathies in the United States and is 
now being applied to many other regions of the world.29,30 
The newborn screen is done by collecting a blood sample from a heel prick shortly after 
the baby is born, ideally between 24 and 72 hours after birth. With that dried blood spot, isoelectric 
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focusing is used to determine the sickle cell disease status. HbS, HbC, HbE, HbO Arab and HbD 
are the most common variants, and these can be confirmed using DNA probes. In Pennsylvania, 
the results are reported to the primary care physician listed on the filter paper as well as regional 
sickle cell centers. That physician is provided with specific instructions on follow-up, referral 
planning, and further diagnostic procedures. The Pennsylvania Department of Health has an order 
of action recommendation, which includes first advising the Department or laboratory which 
Treatment Center/Specialist is being recommended, then contacting that Treatment 
Center/Specialist for a referral and additional information before contacting the family. After the 
information is gathered, the family is contacted to check in on the status of the newborn and refer 
the family to the Treatment Center/Specialist for confirmatory testing and management.31 For 
carriers, the Newborn Screening and Follow-Up Program does not have formal hemoglobin trait 
guidelines, but does recommend consideration of confirmatory testing and genetic counseling. 
There is no immediate clinical significance with most hemoglobin traits, but it may be worthwhile 
to go to the appropriate treatment center for follow-up testing, education, and counseling 
services.32  
2.1.2 Molecular Genetics 
Sickle cell disease has some genotypic variation, and at the molecular level is associated 
with pathogenic variants in the HBB gene. Typically, in individuals who have sickle cell disease 
one of these pathogenic variants is Glu6Val which results in Hb S. About 60-70% of the time, 
individuals are homozygous for this variant resulting in Hb SS disease. In the other cases of sickle 
cell disease, individuals have one pathogenic Hb S, Glu6Val mutation and then another variant 
which might include Hb C (Glu6Lys mutation), Hb D (Glu121Gln mutation), Hb O (Glu121Lys 
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mutation), Hb E (Glu26Lys mutation), or a β-thalassemia pathogenic variant. These are the most 
common variants that lead to sickle cell disease, although others have been identified and reported. 
Sequence analysis is typically required to find these mutations; however, duplication/deletion 
analysis is important in identifying a missing thalassemia allele. 
Sickle cell disease is inherited in an autosomal recessive pattern.33 In a scenario where both 
parents are carriers (also referred to as having sickle cell trait (AS)), with each pregnancy there are 
three potential outcomes: 1 in 4 or 25% chance that the child has sickle cell disease (SS), 2 in 4 or 
50% chance that the child has sickle cell trait (AS), and a 1 in 4 chance that the child has neither 
sickle cell trait nor disease (AA).  
2.2 CARING FOR INDIVIDUALS WITH SICKLE CELL DISEASE 
2.2.1 Providers 
The primary provider for an individual with sickle cell disease is typically a hematologist 
who can help manage medications, prevention, and therapies. The hematologist can refer the 
individuals to appropriate specialists when the time comes. Some of those specialists might include 
a pulmonologist, dentist, ophthalmologist, and cardiologist, to name a few. It is also important that 
an individual with sickle cell disease sees a primary care physician regularly, just like any other 
individual for wellness visits.  
Another specialist that could prove important for caring for an individual with sickle cell 
disease or sickle cell trait is a genetic counselor. A genetic counselor can help the child’s parents 
confirm their carrier status, explain how the condition is inherited, explain the individual risks for 
 10 
that couple, and then give information on options moving forward based on what the couple 
desires. If both parents were confirmed to be carriers, the genetic counselor can discuss prenatal 
testing options as well as assisted reproductive options such as preimplantation genetic diagnosis. 
The genetic counselor can provide psychosocial support for the family because taking care of a 
child with a chronic illness can be a large responsibility, and it is important to acknowledge that. 
For individuals who are identified as a carrier on the newborn screen, a genetic counselor can 
speak with the family to help them understand what this means for the child, and what information 
is important to discuss as the child ages.  
2.2.2 Prevention, Management and Treatment 
Prevention in sickle cell disease can fall into three categories: preventing the disease 
(primary prevention), preventing early complications of the disease (secondary prevention), and 
preventing further complications of the disease (tertiary prevention). The first of these, preventing 
the disease, requires that a parent knows the carrier status for both themselves and their partner. If 
this is information that a couple is interested in or concerned with, there is the option to speak with 
a genetic counselor, or other educated personnel at a sickle cell center.  
Once a child is born with sickle cell disease, the main concern becomes preventing early 
complications of the disease. Management begins at a very young age for individuals with sickle 
cell disease beginning with prophylactic penicillin starting at the age of three months, the flu 
vaccine administered yearly after six months of age, a special 23-valent pneumococcal vaccine at 
age two and five, and a meningococcal vaccine.29,34 Additionally, they are supposed to follow the 
vaccine schedule outlined for all children. 
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The most common causes of death in children with sickle cell disease are infection and 
splenic sequestration crises, with about 66% of children with sickle cell disease younger than age 
six being more susceptible to S.pneumoniae and children with sickle cell disease older than age 6 
being more susceptible to E.coli (30%).24,35 Prophylactic penicillin was introduced in 1986 after a 
study was done by the Prophylactic Penicillin Study Group that assessed the efficacy of penicillin 
prophylaxis in preventing bacterial infections in children with sickle cell disease. The study was a 
randomized, double blind study done over the course of two years in the United States. There were 
two groups, one of which received penicillin V potassium 125 mg twice daily, and the other, 
placebo group, received vitamin C 50 mg twice daily. Patients were monitored every three months 
with a physical examination and a complete blood count. Pill counting and urine samples were 
used to determine compliance. The study ended 8 months early due to an 84% reduction in S. 
pneumonaie  infection and lack of deaths in the penicillin group.22 The mean age of death improved 
after 1978 since the implementation of the special pneumococcal vaccines and prophylactic 
penicillin. The deaths due to infection also revealed a change with 74% of deaths due to infection 
occurring in adults after 1985.24 Fatality in individuals with sickle cell disease due to infection in 
the United States used to be around 35%22, whereas after the implementation of prophylactic 
penicillin that rate is now rare. 
Splenic sequestration must be monitored in young children as well, as many may need 
further intervention. About 94% of children with sickle cell disease, specifically HbSS disease, 
experience vaso-occlusion within the spleen which leads to functional asplenia by the age of five.36  
As many as 11% of children with sickle cell disease may experience a stroke. These strokes occur 
due to partial or complete occlusion of the internal carotid artery, anterior or middle cerebral 
arteries, or vertebral artery.36 Originally it was thought that this was due to the sickling of cells 
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within tiny blood vessels, but showing that the large arteries were responsible revealed that this 
was not the case.36 Later, it was shown that this may be due to perfusion failure as well as 
intravascular sickling.37 One of the measures put into place to help prevent these events are 
transcranial Doppler (TCD), which is a type of ultrasound that measures the blood flow velocity 
through the blood vessels of the brain by measuring the echoes of ultrasound waves moving 
through the brain. It is recommended that a TCD is done annually, starting at the age of 2 years, 
for children with HbSS disease. A child is monitored this way and a normal TCD velocity is less 
than 170 cm/sec. If the flow velocity is at an elevated level of 200 cm/sec or greater38  the child is 
identified as being at higher risk for the development of a stroke.39 The child is started on a 
preventative chronic transfusion program to reduce the level HbS to less than 35%, which lowers 
the risk of stroke by greater than 70%.39 Over the years, the TCD has proved to be a useful and 
valuable tool for stroke detection of risk factors for stroke in individuals with sickle cell disease.38–
40 
Much of management of sickle cell disease is focused on treatment of symptoms or 
complications of the disease. When symptoms occur, they are managed and prevention measures 
that are implemented are to prevent further complications. Prevention and management guidelines 
for sickle cell disease have been created by the National Heart, Lung, and Blood Institute. An 
expert panel consisting of doctors and physician assistants came together to review the available 
scientific evidence about sickle cell disease to assist primary care physicians in caring for patients 
with sickle cell disease. The guidelines suggest preventative screenings for many complications, 
including pneumococcal infection, renal disease, pulmonary hypertension, echocardiogram, 
hypertension, retinopathy, strokes, pulmonary disease, and genetic counseling.4 
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The management of sickle cell disease is very complex, and it is critical as the only current 
cure, or treatment, for sickle cell disease is a hematopoietic stem cell (“bone marrow”) transplant. 
The transplant requires a human lymphocyte antigen (HLA)-donor, typically a family member. 
Beyond needing an exact donor, there are added complications that include a 7% transplant-related 
mortality rate as well as a 9% graft failure rate, meaning the disease-free survival rate is about 85% 
with a perfect match sibling donor.41 Different studies revealed data that contributed to these 
overall findings. One of those studies analyzed 44 patients given allogeneic related cord blood 
transplant for thalassemia or SCD, 11 of which had SCD. None of the patients in this study died, 
and 90% of SCD patients had 2-year event-free survival. It was also found that the use of 
methotrexate for prophylaxis was associated with greater risk of treatment failure.42 In France, a 
study was done over the course of six years between 1988 and 2004 with 87 patients, ranging from 
ages 2 to 22 years. Of note, antithymocyte globulin (ATG) was introduced into the conditioning 
regimen in 1992; this change improved the graft rejection rate, decreasing from 22.6% before to 
3% after including ATG. Overall survival in this study was 93.1%, and the event-free survival was 
86.1%. Graft versus host disease was the main cause of transplantation-related mortality.43 Another 
study revealed that allogenic bone marrow transplantation leads to normal erythropoiesis, as well 
as has a positive impact on the growth and the stability of CNS imaging studies and pulmonary 
function. This study followed twenty six patients for at least two years after transplantation with 
engraftment, and for 22 of 26 of these patients, complications related to sickle cell disease had 
improved.44 
Sickled cells not only cause complications for individuals with sickle cell disease, but they 
also have a much shorter survival, lasting 10 to 20 days instead of the normal 120 days.29 Folate 
levels are then much lower in those with sickle cell disease. Folic acid may be beneficial in the 
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treatment in hemolytic anemia, however there is less data to support folate deficiency and/or the 
need for folate supplementation in sickle cell disease. Some have suggested that folic acid be 
administered on an individualized basis, and that evidenced based medications like penicillin and 
hydroxyurea continue to be used.45  
The first and only medication approved by the FDA for the treatment of sickle cell disease 
is hydroxyurea. This medication has proved effective in reducing hospitalizations, pain crises, and 
acute chest syndrome. The efficacy and effectiveness of the drug have both proved beneficial for 
those individuals living with sickle cell disease. Hydroxyurea has been the most significant benefit 
for those with sickle cell disease, but also needs to be adjusted to the optimal dose and monitored 
closely for toxicity and side effects. There need to be more frequent visits to the hematologist to 
check on blood count and hemoglobin levels as part of that monitoring process. Since this 
medication has shown such improvement for patients, compliance is important, and the drug 
cannot be safely prescribed without regular visits to ensure appropriate dose and to minimize side 
effects.  
2.3 HYDROXYUREA 
2.3.1 History 
The first synthesis of hydroxyurea was done in Germany by Dr. WFC Dressler and Dr. R. 
Stein in 1869.46 Hydroxyurea was originally intended to be used for the treatment of malignant 
and benign growths, such as cancer. The safety of the drug was approved by the FDA in 1967 for 
the use of treating a variety of solid tumors, especially carcinomas in humans.47 There were 
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various clinical trials over the years testing the efficacy of this drug for treating other conditions, 
such as myeloproliferative, neoplastic, and non-hematological diseases, as well as HIV.47 
However, it was not until February 1998 when it was approved by the FDA for use, that 
hydroxyurea was used for adults with sickle cell disease who experienced recurrent moderate to 
severe painful crises. It was not approved for use in pediatric patients with vaso-occlusive crises 
and acute chest syndrome until 2007, and this was only by the European Medicines Agency.48 
Then in 2008, the Agency for Healthcare Research and Quality published a comprehensive 
systematic review and the National Institutes of Health Consensus Development Conference was 
held, both in discussion of the use of hydroxyurea for treatment in individuals with sickle cell 
disease.49,50 Efficacy and effectiveness found in multiple studies was reviewed, showing that it 
was efficacious in children and adults with SCD, reducing pain crises and hospitalizations, as 
well as increasing the percentage of HbF, quality of life and possibly increased survival.  
2.3.2 Drug use and efficacy 
The original study by Charache, Terrin, Moore and Dover that proved the efficacy of 
hydroxyurea in sickle cell disease was run from January 1992 until June 1994 and was ended 10 
months early due to the significant differences between the hydroxyurea and placebo group (1995). 
The study had 134 patients who completed follow-up, as the study ended early and not all of the 
299 patients were able to complete the full two years of follow-up before the study ended. 
Individuals were only included in the study if they were 18 years or older and their sickle cell 
disease was Hb SS or sickle cell-beta0 thalassemia. Hydroxyurea was found to reduce annual rate 
of crises by 44%, increase median time interval to first crisis from 1.5 months to 3 months, and  
increase median time to second crisis from 4.6 months to 8.8 months.51 It is important to note that 
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at this time the efficacy had only been shown in adult patients with sickle cell disease. For children, 
the efficacy of hydroxyurea was shown as early as 1996, but has not yet been FDA approved for 
use in children in the United States. The efficacy of hydroxyurea was evaluated through the events 
requiring hospitalization, which showed that 73% of individuals were not experiencing severe 
enough painful events to be admitted to the hospital while on hydroxyurea. This study included 22 
patients with the median age of 8, and found that there was no relevant toxicity due to 
hydroxyurea.52 Another study assessed thirteen hydroxyurea patients, between the ages of 10 and 
17 years, with HbSS or HbS-beta0 thalassemia. This showed the efficacy through the increase in 
total hemoglobin (1.3gm/dl), MCV (15.5 fl), and level of Hb F (6.9% to 15.2%). Hospitalization 
was also decreased from 4.1 to 1.7 days per month, with all values being statistically significant.53 
Another study looking at 8 children with Hb SS from ages 2-5 years found that hospital admission 
rates decreased by 55% and total hospital days decreased by 60% while using hydroxyurea in 
children with SCD. Transfusions were also decreased by 75% in this group, and Hb F levels 
increased from 6.8% to 19.9%.54  Taken together, these many different studies have shown a wide 
range of benefits for the use of hydroxyurea in sickle cell disease.  
2.3.3 Short and long term effects 
Hydroxyurea has shown improvements for patients with sickle cell disease, particularly 
reducing the morbidity due to complications associated with sickle cell disease55. In the short-term 
usage, it increases the fetal hemoglobin (HbF) levels in adult patients while also decreasing the 
frequency of vaso-occlusive events.55 Long term, the increased levels of HbF have shown 
improvements in both morbidity and mortality. One study reports hydroxyurea usage after 9 years 
of follow up being associated with a 40% reduction in mortality in adults.55 This study included 
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233 patients with complete follow-up data who were recruited from 21 centers throughout the 
United States and Canada.55 In another controlled clinical trial that had originally identified the 
safety and short-term efficacy for hydroxyurea in individuals with sickle cell disease, specifically 
HbSS, continued to follow patients for 17.5 years. At any point during this time, patients could 
start or stop hydroxyurea. The death rate amongst the cohort was high, 43.1%, however, 87.1% 
occurred in patients that did not take hydroxyurea or took it for less than five years. The largest 
cause of death (24%) in this cohort was pulmonary complications.56 
Children who were observed over the course of 5-10 years were found to have no severe 
side effects that were related to the hydroxyurea treatment.57 The treatment was discontinued in 
some patients, but this was due to the failure of the treatment or compliance issues.57 Some studies 
identified many positive long term effects for children with sickle cell disease taking 
hydroxyurea.58–60  After 4 years, some blood specific changes that were observed were increased 
hemoglobin concentration, percentage of HbF, and mean corpuscular volume. In addition, there 
were decreased reticulocytes, white blood cells, and platelets. Acute chest syndrome events were 
significantly reduced, and patients experienced better spleen function and improved growth rates. 
This was one of the first indications that hydroxyurea could possibly preserve organ function.58 In 
a long-term study by Zimmerman et al. that followed 122 pediatric patients over the course of 
eight years, they demonstrated the long-term safety of hydroxyurea.59 There were also no issues 
with growth during this period, even with increased levels of Hb F. The same increases were found 
in this study as the study discussed above.59 The Belgian Registry reported that in following 
patients over the course of six years, there was continued response to hydroxyurea with no 
significant long-term effects noted. This cohort contained 32 patients between the ages of 8 months 
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and 19 years, with 25% of the patients not experiencing sickle cell related issues that required 
hospitalization.60 
Since hydroxyurea is now a widely-used drug for children with sickle cell disease, it was 
important to evaluate the toxicity of the drug to ensure long-term safety and look at negative 
effects. In both of the studies mentioned above, there was no long-term toxicity that was found.59,60 
An additional study done in 2006 with 75 patients between the ages of 17 months and 19 years. It 
revealed information like the two listed above, that hydroxyurea did not reveal any long-term toxic 
effects.57 
Despite all this, not all children with sickle cell disease are taking hydroxyurea. Some 
parents are hesitant to give their child medication before they are symptomatic, and not all children 
are facing the same medical issues, and are doing well overall. Typically, those with HbSS sickle 
cell disease experience complications earlier on in life than those with other variants. Taking 
hydroxyurea requires that individuals be seen in clinic more regularly to make sure their dosage is 
correct, which may hinder individuals from taking this medication as well.  
The research has shown the many positive benefits of taking hydroxyurea for individuals 
with sickle cell disease. It decreases the number of crises and hospitalizations, among many other 
benefits. With a medication that has proven so effective, it is important to encourage individuals 
to make it to their appointments, so that the medical providers can optimize the dose and monitor 
for toxicity, especially with dose adjustments needed for growing children. Promoting appointment 
compliance is crucial in keeping these children healthy by ensuring they are taking their 
medications and doing well.  
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2.4 APPOINTMENT COMPLIANCE 
2.4.1 Clinical no-show rate 
The no-show rate in outpatient clinics is a costly problem that most clinics face, and 
unfortunately it is something that may not be well recorded. When the no-show rate is recorded, it 
is important to take advantage of this information and work towards ways to improve the number 
of individuals attending clinic appointments. The cost of the no-shows includes resources and 
physician time not being used appropriately. At a hospital based in Alaska, the no-show 
appointment total in 2015 was 13,344 patients, costing the hospital an estimated $2 million, 
ranging from about $176-$202 per missed appointment.61 It is important to note that this cost is 
likely much higher in a multidisciplinary clinic. In a family clinic in Palmetto Richland Memorial 
Hospital/University of South Carolina, no-shows and cancellations accounted for 31.1% of 
scheduled appointments, and cost the hospital anywhere between 3%-14% of annual income.62 At 
a large medical center that included 10 regional hospitals at the Michael E. DeBakey VA Medical 
Center in Houston, Texas, it was found that in 2008 the cost per patient that did not attend their 
appointment was $196.63 More importantly, it negatively impacts the quality of the care the patient 
might receive and thus the satisfaction with that care. In a focus group of physicians, it was found 
that patients who missed appointments were viewed negatively, and some physicians 
recommended charging patients for these missed appointments.64 This creates tension between the 
doctor and the patient and could then impact how the patient perceives the interaction in the future.  
It is essential for individuals with chronic conditions, like sickle cell disease, to be seen in 
an outpatient clinic on a regular basis to receive their medications, immunizations, TCD screens, 
check blood counts, and adjust the care as needed as an attempt to prevent crises and complications, 
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as well as emergency department visits.4 Without these appointments, individuals with sickle cell 
disease could be at an increased risk for life-threatening conditions, including pneumococcal sepsis 
and stroke. With the advancements that have been made and the clinics that make that care 
possible, the lifespan of those living with sickle cell disease has increased to somewhere between 
42 and 48 years old for those with HbSS 3, compared to the 1970s when the life expectancy was 
less than 20 years.65  
2.4.2 Efforts to improve the clinical no-show rate 
As the clinical no-show rate is an issue that clinics all over the country have experienced, 
there is some research about methods that have shown to be effective6,63,66–68. One of the ways that 
has been implemented to increase appointment compliance is reminder phone calls.6,63 It is 
common that clinics have an automated system in place for reminding patients about their 
appointments. However, a personal connection was thought to be more effective, so some patients 
were called by a staff member and other patients were called using the automated system. There 
was a significant difference between the two methods for reducing the no-show rate, with the staff 
reminder calls (n=3266) proving more effective, with a no-show rate of 13.6% compared to the 
automated system (n=3219) with a no-show rate of 17.3% (p<0.01). Both methods reduced the no-
show rate, as was seen by the no-show rate of 23.1% in the control group where no call was made. 
This study showed that the staff and automated calls had more people either come to clinic or 
cancel their appointments than in the group where they were not called.6 Other studies have looked 
at similar situations and found that the reminder calls slightly reduced, but did not statistically 
significantly reduce the no-show rate amongst their patients, making it effective but not ideal.63,66 
In a retrospective cohort study, they evaluated the no-show rate, effect of reminder calls, and cost 
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of no-shows. The study found that reminder calls only reduced the no-show rate from 16.3% to 
15.8%(p = 0.03), and that the average cost per no-show was about $196 in 2008.63 Another study 
also found a reduction in no-show rate from 26% to 19% (p = 0.0065). This study is interesting 
because it also found that telephone reminders allowed more people to cancel or reschedule their 
appointments instead of not showing. That being said, it found no significant difference in the 
show rate in clinic, staying at about 63%. This means that the no-show rate along with cancellations 
accounted for 37% of  total appointments.66 In making these phone calls, studies have shown that 
the ability to actually reach the patient leads to a significantly higher rate of people keeping their 
appointment as opposed to those who were unable to be contacted, either due to no answer or lack 
of a phone.69 Moving forward, knowing the target population and access to a telephone are 
important factors to keep in mind. Most people have phones, but the numbers may change, there 
may be temporary loss of service, and some families do not have phones.  
2.4.3 Barriers 
Implementing different systems to encourage appointment compliance is incredibly 
important, and to find the best solution it is necessary to find out why people are not attending 
appointments in the first place. Since there has not been a consistent method that has proved 
effective, studies have been conducted to discover these patient-perceived barriers. In one study 
patients consistently identified three different themes: emotional barriers, disrespect of beliefs and 
time, and distrust and lack of understanding of the scheduling system.5 Emotional barriers 
consisted of not wanting to hear bad news that is typically associated with going to the doctor, or 
the patient was not feeling ill at the time so there was the lack of urgency. The view of disrespect 
stems from the amount of waiting that takes place, either in the waiting room or in the examination 
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room. Patients feel as if their time is not taken into consideration. Lack of understanding in this 
case means that patients did not realize the cost of the no-show and how that impacted a clinic. It 
was perceived that the clinicians were happy about this because it was less work for them. Other 
common themes that came out of this study that was previously reported by other studies as well 
were transportation and child care issues.5 It is important to note that the population for this study 
was an adult population. 
Perceived barriers in a pediatric sickle cell disease clinic have also been specifically 
studied, which is the most applicable study to be extrapolated for this project. The study population 
included 32 adolescent patients, aged 13-21 years from three sickle cell clinics in the Mid-west.8 
The most common barriers that were reported were competing activities, feeling healthy and well, 
relationships with the provider, poor clinical experience, and forgetting. Semi-structured 
interviews revealed that appointment reminders seemed to be the most effective way to preventing 
the no-shows as well as flexible scheduling to accommodate competing activity issues. One way 
that was suggested for assisting with this was having evening appointment times. Interventions 
that could also impact appointment compliance are reminders, both in the form of phone calls and 
text messages. As far as addressing the issue of patients not attending clinic when they feel well, 
more education may be beneficial for informing individuals about why it is so important for their 
care and further wellness to regularly attend clinic visits.8 
Although there is limited data with the sickle cell patient population, research has been 
done in other populations on barriers to appointment compliance. Forgetting is a common theme 
that is proposed for non-compliance. A randomized controlled trial of appointment reminders was 
done at Royal Children’s Hospital in Melbourne, Australia, which sees patients ages 12-19 years. 
This study found that telephone reminder phone calls in the adolescent population reduced non-
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attendance by 60%, from 20% to 7.9%. Participants were also surveyed and of those in the control 
group, 81% reported that reminder calls would be helpful, and in the reminder group, 77% reported 
that the calls were helpful.70 In a diabetic nutritional care clinic, 293 patients undergoing outpatient 
treatment were surveyed and had their charts reviewed to determine non-attendance to clinic visits. 
The results of the study found that nonattendance was associated with many factors, including 
satisfaction with the provider and the utility of the appointment.71 Satisfaction with the provider is 
a theme that occurred in another study in San Jose, California. The study found that the patients’ 
satisfaction was highly correlated with appointment compliance. Females and older adolescents 
were more commonly satisfied and thus had a higher appointment compliance.72 
In the sickle cell clinic at Children’s Hospital of Pittsburgh of UPMC, providers started to 
observe that some changes might be necessary to provide the best care for the patients. Some 
families who were being seen for hydroxyurea follow-up informally expressed interest in having 
fewer clinic appointments and that they were coming to the clinic too often. This led to the 
implementation of having the frequency of appointments go from every month to every two 
months for patients who were on a stable dose of medication with no sign of toxicity and were 
considered safe to lengthen the time between monitored visits.  Appointment compliance is 
something that all clinics aim to improve, and the sickle cell clinic wanted to be sure everything 
was being done to assist patients in coming to their appointments. Since patients commonly 
identify forgetting their appointment as a barrier, the standard of care changed to having a person 
call for appointment reminders in addition to the automated system. The hydroxyurea follow-up 
appointment frequency change in standard of care was initiated in September of 2015, and the 
personal phone call reminders began in September of 2016. 
 24 
3.0  MANUSCRIPT 
3.1 BACKGROUND 
Sickle cell disease is a condition that is caused by sickling red blood cells and causes severe 
complications such as infection and severe painful crises. It affects approximately 100,000 
individuals in the United States and about 1 in 365 African Americans.2 While African Americans 
are primarily affected, it is of note that they are not the only population that is affected. Historically, 
the most common complication leading to death in sickle cell disease was infection, leading to 
fatality about 35% of the time. The efficacy of prophylactic penicillin was demonstrated in 1986, 
showing an 84% reduction in S.pneumonaie infection.22 It was this study that revealed that early 
intervention was important for survival for individuals with sickle cell disease, which eventually 
led to the nationwide addition of sickle cell disease to state newborn screening panels. With this 
policy implementation, more young children are being diagnosed with sickle cell disease, allowing 
them to be followed from an early age to prevent life-threatening complications.  
For patients with sickle cell disease, it is imperative to be seen regularly for medications, 
checking blood counts, and adjusting care to prevent painful crises and complications.4 
Management begins at a very young age for individuals with sickle cell disease beginning with 
prophylactic penicillin starting at the age of three months, the flu vaccine administered yearly after 
six months of age, a special 23-valent pneumococcal vaccine at age two and five, and a 
meningococcal vaccine.29,34 Further management guidelines for prevention have also been outlined 
by the National Heart, Lung, and Blood Institute.29 Hydroxyurea is the most recent addition to the 
recommended management guidelines for individuals with SCD, showing many improvements in 
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reducing the morbidity due to complications associated with SCD55,58, with limited toxicity57,59,60. 
Follow up becomes even more critical for individuals taking this drug, as it is important that they 
maintain an effective yet healthy dose.  
Lack of appointment compliance, or high no-show rates, is a problem that is consistent 
throughout outpatient clinics across the country and worldwide.6,63,66–68 Not all clinics have a good 
system for tracking this, but some have been able to track not only the no-show rate but the cost 
that comes along with that missed appointment. Research has shown that a single no-show can 
cost a healthcare system between $175-$200.61–63 
One common reason for missing appointments has been found to be forgetfulness.8 Many 
institutions have an automated reminder system in place; however, others have seen an 
improvement when using personal reminder phone calls.6,63 Both studies showed slight reduction 
in the no-show rate, and increased the number of patients who were calling to cancel and 
reschedule appointments. Patients cancelled more appointments than just not showing, but 
interestingly, it did not improve the show rate of about 63%.63 A study by Parikh et al. found a 
significant difference between automated calls and personal phone calls.6 The no-show rate 
differed with automated calls having 23.1% no-shows and personal phone calls having 17.3% no-
shows, and the study found that more individuals were canceling their appointments. In a separate 
study, patients reported that reminder phone calls were or would be helpful to encourage them to 
attend appointments.70 Studies have also found that respect for the patients’ time was important in 
encouraging appointment compliance, because sometimes patients feel that their time is not taken 
into consideration.5 
The Pediatric Sickle Cell Program at the Children’s Hospital of Pittsburgh of UPMC has a 
comprehensive multi-disciplinary team and serves about 250 patients from birth to age 22.  In the 
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sickle cell clinic, providers started to observe that some changes might be necessary to provide the 
best care for the patients. For example, patients who were being seen for hydroxyurea follow-up 
expressed interest in having fewer clinic appointments and stated that they were coming to the 
hospital too often. This led to the implementation of having the frequency of appointments go from 
once every month to once every two months for patients who were doing well with the medication. 
Patients were identified as doing well on their medication when their blood counts remained 
consistent at a particular dosage. This change was implemented in September of 2015. The 
Pediatric Sickle Cell Program later decided to implement reminder phone calls because patients 
commonly identified forgetting their appointment as a barrier.  In September of 2016, the standard 
of care in the clinic changed to include having a person call patients for appointment reminders 
both seven and two days prior to the appointment in addition to the reminders sent out by the 
automated system.  
 Although there has been some previous research into the barriers to care in young people 
with sickle cell disease8 and studies on the effectiveness of various strategies in reducing the clinic 
no-show rate, this study specifically looks at the separate impacts that fewer appointments and 
appointment reminder calls have on appointment compliance.  In this study we aim to evaluate the 
effectiveness of these standard of care changes in the Pediatric Sickle Cell Program at Children’s 
Hospital of Pittsburgh specifically designed to address to appointment no-show rate by measuring 
this rate during a set time period both before and after implementation of the changes. 
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3.2 METHODS 
The participants for this study were chosen from the pediatric patients diagnosed with 
sickle cell disease who were cared for in the Pediatric Sickle Cell Program at Children’s Hospital 
of Pittsburgh, University of Pittsburgh Medical Center. The participant population included male 
and female patients ranging from ages 0 to 22 who were cared for in the sickle cell clinic. Patients 
of all types of SCD were included in the study.  
3.2.1 Clinic Composition 
The Pediatric Sickle Cell Program at Children’s Hospital of Pittsburgh, University of 
Pittsburgh Medical Center is staffed by a multidisciplinary team of medical specialists including a 
number of hematologists, physician assistants, social workers, nurses, genetic counselor and 
behavioral health specialists. The program was established in 1978, and identifies children with 
sickle cell disease as early as possible to provide management to best care for these individuals. 
The clinic has an annual patient volume of about 210 patients from birth to age 22. This particular 
clinic is included as one of the specialty treatment facilities for newborn screening, thus results are 
sent here and the multidisciplinary team works with families to provide appropriate follow up care 
through the clinic. 
3.2.2 Policy Changes 
The Pediatric Sickle Cell Program began calling patients to remind them of their 
appointments as part of a standard of care change that was implemented in September 2016.  Under 
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this new office protocol patients were called by a sickle cell team member seven days prior to the 
time of their appointment and then called again two days prior to the appointment. The phone calls 
reminded the patient that they had an appointment, checked to ensure that the appointment date 
and time were still good for the patient, and gave the patient the number for scheduling and the 
opportunity to change the appointment if needed. The patient had the opportunity to cancel the 
appointment when they were called; however, they needed to make an additional call to scheduling 
in order to reschedule. If there was no answer and the patient’s voicemail box was set up, there 
was a scripted voicemail left with the details of the appointment and the number where the patient 
could call to reschedule their appointment. When there were other patient issues that needed to be 
addressed, those were documented and addressed by the appropriate team member. Previously, 
patients were receiving calls regarding their appointment three days prior from an automated 
system, and this continued throughout the change as well.  
The second standard of care change that was made in the Pediatric Sickle Cell Program 
was a change in appointment frequency for patients who were being followed for hydroxyurea 
management.  These individuals previously were scheduled for an appointment to be seen every 
month. In September 2015, this requirement was changed to having an appointment scheduled 
every two months if the dose of medication was not changed and there were no concerns from the 
history, physical examination and laboratory studies.  The patients who were seen both before and 
after this change were used to compare the no-show rate within this population before and after 
the policy change. This was done to determine if changes to the appointment frequency were 
effective in encouraging patients to attend their appointments. 
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3.2.3 Phone Call Participants 
This participant population included patients who had at least one appointment in the 
Pediatric Sickle Cell Program over a 6-month period from September 2015 – February 2016 (prior 
to the implementation of additional reminder phone calls) and September 2016 – February 2017 
(after the implementation of additional reminder phone calls).  For inclusion in this portion of the 
study, participants needed to be called with an appointment reminder during the 6-month period 
from September 2016 – February 2017, and had to have appointments in the same time frame in 
the year prior. Individuals that were unable to be called during the phone call reminder time period 
were excluded from the study. The phone call reminder change was implemented in September 
2016. The number of individuals included in this portion of the study is 101. 
3.2.4 Hydroxyurea Participants 
This participant population included patients who had at least one appointment in the 
Pediatric Sickle Cell Program over a 12-month period from July 2014 - June 2015 (before the 
change in appointment frequency) and January 2016 – December 2016 (after the change in 
appointment frequency. For inclusion in this part of the study, patients had to be taking 
hydroxyurea during both time frames stated above. Individuals who were not seen during both 
time frames or were not taking hydroxyurea during both time frames were excluded from the study. 
The change in frequency of appointments from every month to every other month occurred in 
September 2015. The number of individuals included in this portion of the study is 67.  
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3.2.5 Data Collection 
The data were collected from the electronic medical record and coded. A no-show is 
counted when the patient does not show or cancels on the day of the appointment.  Appointments 
that were cancelled prior to the day of the appointment were not included the dataset and did not 
count against the no-show rate. The data points that were collected included date of appointment, 
appointment status (cancelled, no-show, or completed), date of cancellation, sex, date of birth, and 
hydroxyurea status (for appointment frequency change). 
3.2.6 Statistical Analysis 
The data were collected from before and after these two standard-of-care changes were 
implemented. The appointment compliance before and after these changes were compared using 
paired analysis to determine statistical significance of the changes to the no-show rate. The data 
were not normally distributed so Wilcoxon signed rank test and a permutation test were done using 
Stata 2.0. Appointments that were cancelled before the day of the appointment were considered 
cancelled appointments as opposed to a no-show. These cancelled appointments were not included 
in the data, as cancelling prior to the appointment allows for someone to be rescheduled in the time 
slot. Descriptive statistics revealed the no-show rate, male to female ratio, and average age, and 
these were done in Microsoft Excel for Mac 2016. The data for each group of participants were 
considered separately. Patient names were coded and there was some overlapping patients between 
the groups. For those who had more than one appointment during the eligibility times, all 
appointments were included in this data set.  
 
 31 
This study was approved by the University of Pittsburgh IRB.  
 
3.3 RESULTS 
The results of this study provide information about the efficacy of the standard of care 
changes that were implemented in the Pediatric Sickle Cell Disease Clinic at the Children’s 
Hospital of Pittsburgh. The two changes that were being evaluated were a change in appointment 
frequency for hydroxyurea patients from every month to every two months, and an increase in 
personal phone call reminders to all patients.  
3.3.1 Personal Phone Call Reminders 
The individuals who were included needed to be seen both before and after the 
implementation of the additional phone call reminders, giving a total of 101 patients included in 
this analysis. The composition of this group included 46 females (46%) and 55 males (54%), 
ranging in age from 1 year to 21 years with an average age of 11.1 years (Table 1). The 
implementation of personalized phone calls started in September 2016, and the data were reported 
for this six month period and compared to the same six month period in the year prior. In the six 
months before the standard of care change was made, the overall no-show percentage was 28.5% 
(103/362 clinic visits). After the phone call reminders were implemented, the percent of no-show 
was 26.5% (76/287 clinic visits). The phone call reminders slightly reduced the no-show rate; 
however, it was not a statistically significant change (p-value = 0.3421) using a Wilcoxon signed 
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rank test. The 95% confidence interval for the median difference between the no-show percentages 
was from -12.5% to +5.8% (rate: -0.125 to +0.058). A decrease of 12.5% would be the equivalent 
of one fewer no-show per 8 appointments and an increased no-show percentage of 5.8% would 
equal approximately one more no show per 18 appointments.  Since an improvement of one no-
show per 8 appointments is likely to be considered clinically significant by most clinics, we do not 
have enough information from the number of patients in this study to determine the true effect and 
it is possible that a larger study would find a significant difference. Improved appointment 
compliance was seen for 35.6% (36/101) of patients after the implementation of the additional 
phone-call reminders, a decline in compliance was seen for 35.6% (36/101) of patients and 28.7% 
(29/101) remained the same. Of note, 22 out of 29 of those whose no-show rate remained the same 
were individuals who did not miss a single appointment (100% show percentage) in either time 
frame, with only 1 out of 29 being someone who missed all of their appointments (0% show).  
3.3.2 Hydroxyurea Appointment Frequency 
We studied 67 patients who were prescribed hydroxyurea during both periods of 
observation for this study. The patients’ ages ranged from 2 to 22 years with the average age being 
12.06 years. There were 33 (49%) females in this population as well as 35 (51%) males (Table 1). 
The hydroxyurea change in standard-of-care occurred in September 2015, so the data was collected 
regarding appointment compliance for June 2014 – July 2015 and January 2016-December 2016. 
Both of these time periods are a full calendar year that includes all seasons of the year. From June 
2014-July 2015, there were 467 appointments scheduled for the participants (Before) and from 
January 2016-December 2016 there were 391 appointments (After).  The percent of no-shows in 
the Before time period was 25.2% (118/467). In the following year the After no-show percentage 
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was 27.8% (108/391). The same 67 patients were included in both the before and after groups, and 
the Wilcoxon signed rank test revealed no significant difference between the two groups in the no-
show rate (p value = 0.6818). The 95% confidence interval for the median difference was -11.9% 
to +7.4% (-0.119, 0.074). This means that the true effect could range from one fewer no-show out 
of 8.4 appointments to an extra no-show per 14.5 appointments. Similar to the Phone call study, 
an improvement of one no-show per 8 appointments is likely to be considered clinically significant 
by most clinics. Therefore, we do again not have enough information from the number of patients 
in this study to determine the true effect and it is possible that a larger study would find a significant 
difference. 
The personal reminder phone call implementation happened during the second time period 
for the patients taking hydroxyurea. While the same individuals may not be in both the 
hydroxyurea and phone call group, we wanted to see if the addition of the personal reminder call 
had any effect on no-show rates. Interestingly in the hydroxyurea group before the phone call 
change was made in September 2016, the percent of no-shows was 28.5% (77/270) and after the 
phone call reminders the percent of no-show clinic visits was 25.6% (31/121).  
Upon further evaluation, we found an improvement in compliance for 39.7% (27/68) 
patients, a decline in compliance in 39.7% (27/68), as well as 20.6% (14/68) patients whose 
compliance stayed the same. For patients who stayed the same, 10 out of 14 were individuals never 
missed an appointment (100% show), with 3 of these patients having 11 appointments in the first 
time range alone. None of these individuals missed all their appointments (0% show).  
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Table 1. Summary of Results 
 
3.4 DISCUSSION 
The standard of care changes made by the Pediatric Sickle Cell Program to improve 
appointment compliance provided information about these specific changes and how to effectively 
move forward.  
This study assessed the effect of implementing reminder phone calls at 7 days and 2 days 
prior to the appointment on the clinic no-show rate.  The no-show rate prior to implementing the 
personal reminder phone calls was 28.5%, and after implementation it was 26.5%, but this result 
is not statistically significant. In combination with prior research63,66, this study shows that phone 
calls do not prove effective in reducing the no-show rate. The results of this study differ in the way 
the study was designed. There was always an automated system in place at our institution, whereas 
one previous study compared having no reminder calls to implementing both automated and 
personal phone calls at the same time as separate interventions. In the future, it might be essential 
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to consider other methods of communication. In a world that has become more technologically 
savvy, the implementation of a routine email or text messaging system could prove effective. 
Allowing a patient to cancel via text message might make for an easier scheduling process as well. 
Other ways that the phone call system could be changed to be more effective might be to do 
targeted calls for patients who have a higher no-show rate, while dropping the calls made to those 
who consistently have 100% compliance. 
Based on the data from the change in appointment frequency for the patients taking 
hydroxyurea, it seems as if this is not enough to improve appointment compliance. The no-show 
rate prior to decreasing the appointment frequency for this group was 25.2% and after 
implementation, the no-show rate was 27.8%, but this was not statistically significantly different. 
Even though this intervention did not result in decreasing the number of no-show appointments, it 
may be that it does improve ease of access for some individuals, but this was not assessed as part 
of this current study.  The number and frequency of clinic appointments was thought to be an issue, 
but in this limited assessment, the implemented changes were not shown to lead to significant 
change in no-show rates. While the results from this study do not show reason to continue with 
this policy, different results may be found if this was looked at for a longer period of time giving 
the opportunity for more individuals, or different individuals, to be included in the data.  
Further analysis was done to see if a combination of both, a change in appointment 
frequency for hydroxyurea patients and personal phone call reminders, was useful in improving 
appointment compliance. There was a portion of these time frames that overlapped, and we were 
able to look at those no-show rates. There were some individuals that may have overlapped in 
these two groups, however in the hydroxyurea group before the personal phone call reminders the 
no-show rate was 28.5% and after it was 25.6%. These preliminary results do show a decrease in 
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the no-show rate, but further research would need to be done in order to determine whether these 
two interventions together make a statistically significant difference in the no-show rate.  
There are a several limitations that exist in this study. One of the limitations includes the 
short time period over which appointment compliance was evaluated. To see significant changes, 
it may require studying these implementations over a longer period of time and/or with a larger 
number of patients. Many things can change over the course of years, including a difference in 
staffing, direction of the clinic, and policy implementations. For our clinic in particular, we 
certainly had many changes over the time period being studied. During this time there was a change 
in the medical director, which can influence the clinic and the patients. There was also construction 
being done to improve the clinic space which can change patient feelings toward coming to clinic. 
Some may feel that this is an additional barrier to coming to clinic and others may feel like this 
gives more urgency to actually attending their appointments. Patient factors can change over time 
as well including number of children needing transportation or childcare, means of transportation, 
changes in living conditions, and potentially guardianship, to name a few. The study looked at 
time periods with one year differences, and with that it means that the age of the child changes. 
The age of the child may be something that influences appointment compliance, and may warrant 
further research to tease apart these factors.  The other factor hindering the efficacy of the standard 
of care changes is the prior rate of no-shows. The appointment compliance in the clinic, even 
before these changes, was 75% and 72%, in the hydroxyurea and phone call groups, respectively. 
This is a much higher show rate than has been previously reported in similar sickle cell clinics.63,66 
This may indicate that this patient population already realizes the importance of regular care in the 
management of their condition, and appointment no show rates may be due to unanticipated 
reasons that would not be impacted by either of the changes implemented in this clinic. Since our 
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show rate was higher than those reported in the literature, it becomes harder to make significant 
changes to the improvement of the no-show rate. Both comparison groups only looked at 
individuals who were seen both before and after the change was made. It might be important to 
consider adding these individuals to the data as it does not include the new patients being seen in 
the clinic. There is, however, a strength in that there was a seasonal month-matched designed.   
Previous studies have looked at additional barriers to appointment compliance including 
feeling well, waiting times, transportation issues, child care issues, and competing activities. 5,8 
For this population, it seems as if forgetting may not be the issue, as the reminder calls were not 
effective in improving the no-show rate. These other barriers could be issues that are affecting our 
patient population as well. Transportation, for example, was not assessed, but in a metropolitan 
area it is not uncommon for individuals to rely on public transportation. Additionally, since many 
families are composed of more than one child, it is not unreasonable to think that lack of child care 
would be a barrier for families. Both were not assessed and could be considered for potential 
barriers. There was no information reported in this study on why patients were not attending their 
appointments, so this might be an important point of further research. While child care issues may 
be difficult to address, transportation barriers might be easily managed by offering transportation 
assistance during phone call reminders. The clinic currently provides transportation assistance to 
return home in the form of gas cards to families. It would be helpful to enhance this with the use 
of offering assistance through CSCF to get the patients to their appointments.  
Since there seem to be many other barriers being reported in the literature, it would make 
sense to first ask the patients what prohibits them from coming to clinic appointments. One way 
to initiate the information-seeking process would be to survey the patients, and give them a chance 
to report what their perceived barriers are and what the clinic could do to assist them. It is important 
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to understand what the real cause for lack of appointment compliance is before any further changes 
can be made. Once the needs of the patient are understood, the clinic can move toward making 
changes that positively influence the patient population that they are serving. 
Future research should focus on some other proposed or patient perceived barriers. It would 
be interesting to see if there were any differences in appointment compliance for those who are 
attending clinic from a distance. This would be useful in creating ways to make clinic more 
accessible through transportation funds or potentially through outreach clinics. The lessons that 
were learned from this study are that not all clinics are the same, and the population can differ. 
This leads to difficulty extrapolating other clinics barriers. It is important to look within for the 
answers because what is believed to be the barrier can be very different from what is actually the 
barrier. While there are many ways to move forward with further research surrounding this topic, 
it may be important to continue to look at the data that is already available. Some other factors to 
consider as sub-analyses to these data would be looking at differences based on factors such as 
age, sex, and distance from the clinic, to name a few. These are potentially factors that make a 
difference within the clinic and would therefore be important to consider for future research with 
this study in this clinic.  
Overall this study provided the information that our clinic no-show rate probably did not 
benefit from a change in frequency of appointments or additional reminder phone calls. Based on 
the confidence intervals, it is possible that a longer or larger study may find a clinically significant 
improvement as these changes go forward.  To further improve the standard of care and 
appointment compliance, different changes may need to be implemented. As this study 
emphasizes, it will be important to continue to track these changes in care to assess their impact in 
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the real clinic setting. These changes should be based on patient-perceived issues, to make sure 
the patients are benefitting as much as possible to encourage attendance to clinic visits 
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4.0  SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC HEALTH 
Individual compliance to scheduled appointments is important across many fields 
throughout the healthcare system, including genetic counseling and public health. Genetic 
counselors and genetic counseling as a profession may be more directly impacted by patients not 
showing up for appointments than other public health professionals. As a profession, genetic 
counselors are in high demand and there are currently not enough people being educated quickly 
enough to fill all of the available positions.73 That being said, it is important to understand how to 
help individuals keep their appointments, since time with genetic counselors is limited.  
In order for the health of the public to be at its best, it is important for public health workers 
to be aware of appointment compliance for the individuals they are serving. There are still some 
public health departments that provide services for individuals so it is important for public health 
professionals to be aware of what works to encourage patients to adhere to appointments. Services 
that are provided include primary care, cancer screenings, and vaccinations amongst others. With 
the specific services they provide, there are often medical staff on site, and time and resources may 
be limited. Often, public health departments are providing services with a very low budget. Missed 
appointments, when there is limited time and resources, cause individuals with limited access to 
potentially miss some of these essential services. Public health departments cannot afford to have 
people missing appointments with frequency, otherwise their resources are depleted and fewer 
people are cared for. Thus, it is important that effective methods to encourage appointment 
compliance are also researched in the field of public health.  
When patients do not attend their scheduled appointments, it is a cost concern for the 
hospital, can make it difficult for counselors to legitimize their time, and can act to extend already 
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long wait times for an appointment. The cost of a no-show for a hospital is estimated to be about 
$200 per no-show, but this is for a general clinic appointment and not specific to a genetic 
counselor or other specialty provider.61,63 If patients are not attending, it may become even more 
difficult for hospitals to see the worth of genetic counselors who often measure their effectiveness 
via number of patients seen. Missed appointments add to this problem because alternate patients 
cannot be scheduled in an appointment slot of a person who no-shows. The cost of no-show 
appointments combined with sometimes limited access to genetic counselors can compound to 
make this issue an important one for genetic counselors and the hospitals or clinics that employ 
them. 
Clinical genetic counselors typically operate in a health care setting with scheduled 
appointment times and often have significant appointment waitlists. Genetic counselors are in very 
high demand with many jobs available, and not enough educated professionals to fill these 
positions. As one might imagine, for a health care provider who is in such high demand, wait lists 
can exist and become backed up very quickly. There are many individuals who need to be seen by 
a genetic counselor, and those who are missing appointments take away the opportunity for 
someone else to be seen. Since there are not enough genetic counselors to see all patients who need 
to be seen, physicians have been encouraged to order testing themselves or put other providers in 
a position to do so74,75, and no-show appointments could result in an increase in this conduct. While 
some doctors may have experience and the skill set to offer genetic testing with the proper 
information and counseling, many do not. Many physicians who order genetic tests have limited 
genetic knowledge; therefore, the patient is not receiving enough information or may even be 
receiving information that is not correct.74  
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Genetic counselors have worked hard in some states to obtain licensure, but in other states 
that do not have licensure, it can be more difficult for counselors to bill for services, order tests, 
and be recognized as the experts in providing genetic counseling services.  There are currently 19 
states that have established licensure for genetic counselors, 3 states in rulemaking, and most of 
the other states are in progress towards obtaining licensure.73 Licensure can help genetic 
counselors increase their value to a hospital. With licensure, genetic counselors are often better 
able to bill for their services and their time, and in some states they are even able to order their 
own genetic testing. The ability to bill for services is important because when this does not occur 
the hospital must cover the cost of the genetic counseling. This cost combined with the decreased 
efficiency and increased cost due to no-show appointments may become prohibitive to a hospital 
hiring new genetic counselors to meet patient needs.   
Genetic counselors are important and can provide services to a broad spectrum of 
individuals in many areas including cancer genetics, prenatal genetics, pediatric and adult genetics, 
cardiogenetics, neurogenetics, and many more. Sickle cell disease is a part of a group of 
hematologic conditions, many of which are genetic, thus benefitting from the services a genetic 
counselor can provide. Genetic counselors can be a part of the comprehensive sickle cell programs 
that exist around the country where individuals identified on the newborn screen are referred. 
When an individual is identified with either sickle cell trait or disease, it is important to discuss 
inheritance, risks to other family members, management, reproductive options, and genetic testing. 
Genetic counselors are specially trained to provide this type of information to these individuals 
and their families, as well as provide that psychosocial counseling. Appointment compliance 
would be especially important for individuals affected with conditions found on the newborn 
screen since treatment is often recommended to start early.  Since these patients generally need to 
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be seen in a set time span, no-show appointments may result in added stress on a clinic and its 
providers. 
From a public health perspective, appointment compliance is important for several reasons. 
When looking at the three core functions of public health, appointment compliance is important in 
each of these three areas, assessment, policy development, and assurance. Under the function of 
assessment, the focus is monitoring health status and diagnosing health problems within the 
community. Individuals with sickle cell disease need to adhere to their appointments in order for 
their health to be appropriately monitored. Sickle cell disease is also included on the newborn 
screen as a way to identify individuals with this particular health condition who are then followed 
through clinic appointments for diagnosis confirmation. In addition, the diagnosis of their further 
health complications are identified through their clinic visits, and this can only be done when 
individuals are attending their appointments.  
Policy development relies on understanding what methods are effective in reducing the 
number of individuals who are not attending clinic visits. This study directly relates to policy 
development because it provides an evaluation of policies that have been put in place at the clinic 
level.  Evaluation is an important aspect of public health policies and interventions because it 
allows practitioners to assess whether the changes are working.  In this study, the evaluation has 
thus far shown that the standard or care changes have not affected appointment compliance.  This 
may inform future changes to the policies in order to best address appointment compliance in this 
population.   
The core function of assurance is addressed by providing care to people, and this becomes 
more difficult if patients are not attending their appointments. The other main component of 
assurance is evaluating the accessibility of services, which is exactly the aim of the project. 
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Standard of care changes were evaluated to see the effectiveness in overcoming barriers to 
appointment compliance for individuals with sickle cell disease.  
Attending appointments helps to keep people healthy, especially those individuals who are 
living with a chronic illness. Not only have no-show appointments been shown to be costly to 
hospitals and clinics, but hospitalizations and emergency department visits can increase the cost 
of healthcare spending, and these visits can increase without consistent care. The lifetime cost of 
care for an individual with SCD estimated to be $460,151 in 200976, which is both a  concern for 
public health and policy officials and a potentially significant burden on individuals and families 
experiencing this disease. Pain crises are one of the most common complications of sickle cell 
disease, and many individuals are admitted to the emergency department because of this. 
Emergency room providers may be unfamiliar with the details of sickle cell disease, which can 
result in delayed care or care that does not follow established guidelines.  
The goal of public health as a whole is to ensure the health and well-being of all individuals 
collectively. When someone with a chronic illness is not attending regular visits, this can result in 
complications and can impact not only their health and quality of life, but also adversely effect 
family and friends around them. If a child with sickle cell disease is sick, they cannot attend school, 
and parents either need to find child care or take off work, and the financial  and emotional burdens 
quickly add up.77 These issues are better managed or prevented when individuals are regularly 
attending clinic visits.4 Since appointment compliance is so important, it is critical from a public 
health perspective to see what methods best encourage this behavior, and these implemented 
methods need to be evaluated in order to determine whether they are working and/or if other 
practices might be more useful to the patient population. Once barriers are identified, public health 
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programs could provide critical resources to help patients and their families overcome obstacles 
and successfully access the care they need for their health and well-being.  
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5.0  PUBLIC HEALTH ESSAY 
5.1 BACKGROUND 
Patients not attending their clinic appointments is an issue faced by healthcare systems 
across the country, and beyond. Patients cannot receive the care they require, and health 
professionals miss out on a chance to help other individuals when individuals do not adhere to 
scheduled appointments. There is also an associated cost to the healthcare system, both in the form 
of cost of the no-show, but also the cost of complications associated with lack of preventative care. 
In an attempt to increase appointment compliance, many institutions have implemented systems 
to encourage attendance, most commonly including reminder phone calls.6,63,66 Our clinic 
implemented a system of reminder phone calls and did not find a significant difference in the no-
show rate. The study found that over a six month period with phone calls, the no-show rate did not 
change significantly from a six month period where personal reminder calls were not being done.  
In this study, reminder phone calls did not seem to significantly improve the no-show rate, 
suggesting that other barriers may be important.  
In order to optimize future interventions aimed at increasing appointment compliance, it is 
important to gain an understanding of patients’ perceived barriers. There have been a number of 
studies done in various clinics to better understand what some of these barriers might be. In a study 
where a population of children with sickle cell disease was specifically assessed, some common 
barriers were competing activities, feeling well, provider relationships, and forgetting their 
appointments.8 Suggestions on how to improve appointment compliance given these barriers 
consisted of appointment reminders and scheduling flexibility. In other clinics, not specific to the 
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sickle cell population, forgetting as well as satisfaction with the provider and utility of the 
appointment were identified.70–72 Other barriers to care can include transportation, childcare, and 
prior work commitments that influence the ability to come to clinic. The literature has shown 
transportation to be a barrier that effects many people, including minority groups such as Hispanics 
and African Americans.78–80 
Clinics can differ in their patient population, appointment policies, appointment reminder 
system, and a number of other factors.  Based on these differences, it is important to evaluate the 
population being served by a specific clinic to see what the patients perceive as their barriers to 
appointment compliance. The Pediatric Sickle Cell Program is in an urban location in the 
Pittsburgh area. The clinic cares for patients 0-21 years old from all over western Pennsylvania. 
Since this clinic serves patients from all over the region, some patients are coming from an hour 
or more away. In order to assess perceived barriers to care in the patient population at the Pediatric 
Sickle Cell Program, we developed a survey for our patient population.  The goal of this pilot study 
is to gain an understanding of what our population finds to be their most common reasons for 
missing an appointment and individuals’ thoughts on appointment frequency, as well as giving 
patients the opportunity to identify specific changes that might improve their accessibility to the 
clinic. The results from this pilot study will be combined with future survey results to inform policy 
changes and the development of additional programs that address the barriers identified 
specifically by this population. 
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5.2 METHODS 
5.2.1 Survey Rationale 
The survey was implemented in the clinic to identify barriers to accessibility for the 
patients and their families as part of a new, larger research registry. Appointment compliance has 
been a focus in the clinic, and there have been efforts implemented to improve it. When new 
policies or protocols are made in a clinic, it is important to make sure they are effective and are 
addressing actual needs of the patient population. To ensure that further implementations are most 
likely to be effective, we felt we first need to go to the patients and their parents/guardians to see 
what their perceived barriers to attending appointments are. The survey was the tool that we felt 
was best to gather feedback on perceived barriers from patients.  
5.2.2 Survey Design and Description 
The survey consisted of four questions as well as space for the parent of the patient or 
patients over the age of 18 to provide any additional suggestions for us to make coming to 
appointments more accessible and beneficial to them. Three of the four questions gave patients the 
opportunity to check as many choices as they felt appropriate, as well as an “other” option where 
they could be more specific with responses. The fourth question was an open-ended question to 
allow participants to state what the most important reason for missing an appointment was. We 
wanted participants to be able to select all issues that applied to them and give additional input, 
because barriers to care is often a multi-faceted issue with multiple barriers often affecting access 
to services.  We also thought it would be useful to know the most important of these barriers. The 
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options that were added to the survey for patients to select from were barriers that had been 
identified via a literature review and the experiences of the sickle cell team.   
5.2.3 Research Registry 
Patients or patients’ parents were only eligible to take this survey after being consented to 
participate in our research registry. Individuals were given the opportunity to then fill out the 
barriers survey, however it was voluntary. The consent for the research registry takes place during 
the patients’ regularly scheduled clinic visits. A member of the research team takes time at the end 
of the clinic appointment to talk with the patients and their parents/guardians about the research 
registry. Consent to the registry allows the research team to look at past, current, and future medical 
records in order to improve policies in the clinic and identify eligibility for future research studies. 
By participating, patients also consent to having specific demographic information shared between 
the research team and the Children’s Sickle Cell Foundation, Inc. as the two work closely to 
provide the best care and support for families.  
5.2.4 Study Population 
The participants for this study were recruited from the Pediatric Sickle Cell Program at 
Children’s Hospital of Pittsburgh between December 2016 and March 2017. Parents of patients 
under the age of 18 or patients over the age of 18 were asked to participate in this survey. All 
patients were individuals with sickle cell disease, including all types of sickle cell disease. The 
survey was administered after patients were consented to participate in the research registry in the 
Pediatric Sickle Cell Program. Both the research registry and the participant survey were approved 
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by the University of Pittsburgh IRB. The patient population included 11 patients between the ages 
of 3 and 16. There were no exclusions, and anyone attending a clinic appointment was included in 
the study population if they consented and chose to fill out a survey. Participation was completely 
voluntary.  
5.2.5 Data Analysis 
The data was collected from the paper surveys filled out by participants. The information 
was analyzed using descriptive statistics on Microsoft Excel for Mac 2016. Tables and charts were 
also generated using this software.  
5.2.6 Pilot Study 
The results from these surveys are being used as a pilot study to determine preliminary 
results about patient perceived barriers. The surveys were collected from December 2016 to March 
2017, but research with this survey will continue beyond this survey. The goal is to continue to get 
people consented for the research registry, and receive more surveys about ways to improve the 
accessibility to clinic appointments.  
5.3 RESULTS 
The results of this pilot study showed that 91% (10/11) of participants did not think that 
they had too many clinic or hospital appointments (Table 2). The one participant who identified 
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having too many clinic appointments shared that they prioritized which appointments they 
attended by what they felt was most important.  
Table 2. Survey Question 1 
Do you think you have too many clinical or hospital appointments? 
Yes 1 
No 10 
 
Participants could identify barriers to their appointment adherence. When asked what the 
most common reason for missing an appointment was, 54% (6/11) of participants reported that the 
patient not feeling well or being in the hospital as the reason. Transportation was reported by 36% 
(4/11) of participants. Expense of transportation, which was a survey option, was identified by 
27%, and another 9% filled in their own response of “transportation”. At least one participant 
stated that forgetting, weather conditions, and the inability to get off work each were the most 
common reasons for missing an appointment (Table 3). 
 
Table 3. Survey Question 2 
What are the most common reasons for missing an appointment? 
Not feeling well or in hospital or ER 6 
Expense of transportation 3 
Forgot 2 
Poor weather 1 
Unable to get off work 1 
Transportation 1 
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Participants were also asked about ways that accessibility to the clinic could be improved 
in the future (Table 4). The most frequently chosen response was transportation assistance with 
63% (7/11) reporting that this would be helpful in improving their ability to come to clinic. 
Reminder phone calls from Children’s Sickle Cell Foundation, Inc.(CSCF) or the sickle cell team 
and the coordination of appointments on the same day were reported by 18% (2/11) that each of 
these would improve the accessibility. Reminder phone calls – automated from the hospital and 
reminder text messages were also mentioned as ways to improve appointment compliance by at 
least one participant for each response. 
Table 4. Survey Question 3 
How do you feel that this could be improved? 
Transportation assistance 7 
Reminder phone calls – from CSCF or sickle cell team 2 
Having several clinic and testing (radiology or lab) visits coordinated on 
the same day 
2 
Reminder phone calls – automated from the hospital 1 
Reminder text messages 1 
 
5.4 DISCUSSION 
Information from the results of this study confirmed some barriers found to be present 
based on prior research on this subject. In this study, 54% of participants identified that a common 
reason for missing a clinic appointment would be not feeling well or being admitted to the hospital 
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or ER. For individuals with sickle cell disease, it is not unreasonable to think that they would need 
to miss an appointment during an acute hospitalization, especially during seasons when certain 
illnesses are going around or they are experiencing crises. During the cold winter months, sickle 
cell patients are ill more frequently due to the cold causing decreased oxygen in the blood, as well 
as their susceptibility to illness and infection with many sicknesses occurring during this time.81 
However, it might be important to determine whether this is due to not feeling well in particular 
or whether it is due to a hospitalization. If an individual is not feeling well, but not admitted to the 
hospital and still not attending their clinic appointment, then this is a concern. Individuals with 
sickle cell disease should consider coming to the clinic or hospital if there is a severe pain crisis 
and should always immediately seek medical care any time their temperature exceeds 101 degrees 
Fahrenheit.29 There is concern that if individuals are not feeling well and still not going to the 
hospital, that there could be some gaps in patient understanding around this issue that then result 
in gaps in care. As part of the clinic appointment, it is important to emphasize the need to come to 
the hospital when the child is not feeling well. This is also an interesting finding because previous 
studies have found that patients feeling well has been a barrier for appointment compliance, but 
the opposite is true in this population, meaning that different interventions may need to be used in 
a clinic serving individuals with sickle cell disease as opposed to standard chronic illnesses or 
other indications. 
Transportation was a theme observed when participants were asked about common reasons 
for missing appointments, and also ways to improve accessibility to clinic appointments. Only 
36% of participants identified transportation as a reason for missing an appointment, almost double 
that number (63%) reported that transportation assistance would help to improve their ability to 
come to clinic. In the literature, various studies have been done on transportation as a barrier to 
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medical compliance. There have been studies showing that transportation affected 38% - 67% of 
the population, and found that minority groups such as Hispanics and African Americans were 
effected more.78–80 There are currently some methods in place through the social worker in the 
clinic to assist families with some of the burden of travelling home from the appointment. In 
Pennsylvania, particularly, there is a Medical Assistance Transportation Program (MATP) through 
the Department of Human Services. With this program, an application must be filled out, but all 
outpatient services are eligible for this service. MATP offers rides using vans as well as 
reimbursement for mileage or bus tickets. Similar services may be available in other states as well. 
This is an important resource to provide to patients who express the need for transportation 
assistance. Despite this service being available, patients are still identifying transportation as an 
issue, which may mean that this program is not fully meeting the needs of this patient population.  
Should this issue persist with the collection of additional surveys, the clinic might consider looking 
into additional programs to assist with transportation to the clinic for this patient population. 
Other barriers were stated in the survey, but with less frequency. Recognizing that this is a 
pilot study, barriers reported even in low numbers should be considered. Some of those issues 
included forgetting, poor weather, and inability to get off work. Forgetting clinic appointments has 
been something that has been seen in the literature8; however, when studies are done on the efforts 
to address this barrier there have been mixed findings, including our study. Some studies found 
that telephone reminder calls do not significantly affect the no-show rate6,63 and others found that 
it has improved the no-show rate70. Individuals with sickle cell disease react poorly to cold and 
poor weather, so many times parents like to protect them from exposure. Work commitments and 
issues with the weather have been reported in the literature as obstacles for some patients.82 
 55 
Suggested ways of improving appointment compliance included 18% of participants 
stating that they would like personal reminder phone calls from a member of the CSCF staff or 
sickle cell clinic staff and coordinating appointments to have multiple clinic visits on the same 
day. Prior studies have shown that individuals prefer a personal phone call to a call from the 
automated system.6,63,66 However, the literature has provided the knowledge that phone calls in 
general have not been significantly effective in reducing the no-show rate. There have been mixed 
findings in the literature on whether or not it is helpful in improving the no-show rate. A 
retrospective chart review study was done in our clinic to assess the effect of personal phone calls 
on the no-show rate, and the results showed that it did not make a statistically significant 
difference. It is important to note that individuals filling out this survey should have been getting 
the reminder calls, so it is interesting that some are still identifying this as something that would 
be helpful.  This might indicate that some patients are not getting calls, do not have the ability to 
accept voicemails and/or are not listening to the voicemails. Interestingly, one patient identified 
wanting a reminder call from the hospital, which is something that is already routinely done in this 
hospital. In this case it would be important to address if the patient is receiving this call, because 
it could be a matter of the hospital having the wrong contact information. This is a situation that 
can be resolved easily by simply updating the patients’ contact information. Reminder text 
messages were also mentioned by one participant, and recently this, too, has been implemented 
into the automated system.  
Based on the identification of transportation being an issue in our population, it makes 
sense that individuals would find it more convenient to have those clinic appointments 
coordinated. Other reasons this might be convenient for patients is that it would require fewer 
missed days of school or work, as well as fewer days of additional childcare because the 
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appointments will be coordinated on the same day. Having many clinic appointments affects an 
entire family, and easing that burden helps the care of the individual. In the Pediatric Sickle Cell 
Disease clinic, our administrative assistant, who takes care of scheduling, and our social worker 
both work closely with the family and the care coordinators in the hospital to coordinate visits to 
the extent possible.  
In this limited analysis, we did not find patients reporting some barriers that were reported 
in the literature, but because it has been shown to be an important barrier, it may be reported with 
additional study participants. Some of these barriers reported in the literature include the lack of 
child care, feeling well, expense of care, competing activities, utility of appointment, satisfaction, 
wait times, and travel time.5,8 Since patients with sickle cell disease can have a variety of medical 
providers, the number of appointments can add up quickly. Participants in this pilot study did not 
overwhelmingly seem to think that this was a barrier for them, with only one participant finding 
too many clinic appointments to be a barrier. Again, more participants in the study may provide a 
different result.  
In the short time of our project, this pilot study can now be used to identify any barriers 
that can be managed with programs that already exist or provide a rationale to add a new 
intervention. There are some ways to provide transportation assistance to families in the clinic at 
this time. The registry also provides the link to the community based organization (CBO), 
Children’s Sickle Cell Foundation, Inc. and with that link in place, the hospital and CBO can work 
together to best support the families and attendance in clinic. In the future, once a higher number 
of the patients in the clinic have been surveyed, those results will be important to implementing 
more broad and potentially more effective changes. Moving forward it might also be important to 
look at the structure of the survey itself. Some potential responses make analysis and interpretation 
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difficult. For example, the response to one question is “not feeling well or in the ED/hospital”. It 
is important to distinguish between these. Individuals need to come to clinic if they are not feeling 
well, but if they are in the hospital then their acute illness is already being addressed.  
Limitations of this study include the small number of individuals who participated in the 
survey, as this is only a fraction of the number of patients who are routinely seen in this clinic. 
Participants who completed this survey were individuals who made it in to their appointments, and 
thus they may be experiencing fewer burdens than other patients who did not show up to clinic. 
This therefore does not account for data from individuals who are unable to make it to their clinic 
appointments. Patients are also self-selecting into this study, which may result in bias.  Selection 
bias is important to consider in this study, and also as the study population grows. Anyone who 
comes to clinic is eligible, meaning there is no randomization in the data, and that the study 
participants may not adequately represent the desired population, which includes those who have 
failed to make it to clinic. The goal is to address barriers to coming to clinic, and if only those 
attending clinic are filling out the survey, it does not address the barriers of those not coming. 
Those who are not coming could be facing the most significant barriers, and they would be the 
ones that we would want to hear from the most. In this situation, it might be helpful in the future 
to do a survey over the phone or through a mailing. Confirmation bias could also arise in the future, 
as more and more individuals fill out the survey, the research team may look back at this pilot 
study and/or have their own beliefs about what is important. While focusing on confirming their 
beliefs, they might miss out on important themes that emerge. The framing effect could also be a 
bias that exists now and in the future. Different conclusions can be drawn from the same data when 
multiple people are analyzing it. In this study, where transportation came about, some might think 
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that individuals selected this, not because it is an actual issue, but because it would not hurt to have 
that assistance.  
Future research should include the continuation of this survey as well as implementing and 
evaluating an intervention targeted for the most common barrier that arises. The study population 
in this study was small, so it is first important to continue gaining as much information as possible. 
Including as many patients as possible is critical to identifying a problem and solution that would 
impact the largest number of individuals. Once the barriers are found, they need to be addressed 
to the best ability of the clinic taking into consideration available resources. This can be done by 
implementing a clinic-wide intervention that aims to overcome a specific barrier. The effectiveness 
of this policy change would need to be evaluated as well to see the true impact it would have on 
the clinic.  
Pediatric patients with sickle cell disease are vulnerable and it is important to address their 
barriers to access more than the average healthy individual. Having a chronic illness, specifically 
sickle cell disease, can cause many complications if not followed and treated preventatively and 
regularly. When individuals with sickle cell disease face issues that require them to be hospitalized 
many are effected. Parents are unable to go to work, children are unable to go to school, and other 
children in the family need to be cared for, just to name a few. Education for children is important 
and parents maintaining the affordability to care for that child are important to public health. If 
children are unable to attend school and parents are unable to attend work due to hospitalizations, 
this is an issue. Accessibility and equality of care are focused on in much of public health, and 
identifying patient perceived barriers aids in improving the quality of life of the public. 
In conclusion, this survey data provides some insight that could very easily extrapolated to 
the rest of the clinic, and potentially other clinics serving patients with sickle cell disease and other 
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childhood genetic conditions as well. There was some consensus about barriers, and there seems 
to be some reasonable solutions to these issues. Moving forward, it would be beneficial to continue 
to survey individuals who are being cared for in the Pediatric Sickle Cell Program. In the 
meantime, Preliminary data can help to inform current practices to ensure the best quality of care. 
It will also be important to continue to measure the impact of any standard of care changes made 
as we move forward.  
 
5.4.1 Public Health Significance 
There are 10 essential public health services that fall under three public health core 
functions. The public health core functions include policy development, assurance, and 
assessment. Assessment services include monitoring health and diagnosing and investigating 
disease. Policy development encompasses informing, educating, empowering, and mobilizing 
community partnerships, and developing policies. The assurance core function involves 
evaluating, assuring competent workforce, linking to/providing care, and enforcing laws.  
 This pilot study touched on each of the three core functions of public health. As a clinic, 
we were investigating to identify our particular population’s perceived barriers. Policy 
development includes using evidence to create new policies or edit existing policies at the clinic 
level.  In doing so, participants were empowered to give their feedback for improvements, 
providing an evidence-based basis for change while also creating and solidifying community 
partnerships. Also, it helps with assessment because the registry will enable future research to be 
conducted to improve care for this population. As part of the registry, individuals’ information can 
be shared between the research team and the Children’s Sickle Cell Foundation, and getting the 
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patient on board to be a part of the relationship that already exists between the hospital and the 
CBO adds a critical unifier to the relationship. By connecting the families to that CBO, participants 
were linked to care. While the hospital provides the physical care, the CBO can offer the social 
and emotional support that makes for better all-around care. Assurance involves helping to ensure 
that patients are receiving recommended care for their diagnosis and addressing gaps in care. With 
this survey we were able to address the patient-perceived gaps to access in care by identifying the 
barriers that make it difficult for them to attend clinic appointments. By identifying barriers, it 
again helps policy development, but in addition to that it helps individuals make it to their clinic 
appointments, in turn allowing them to receive the recommended care for their diagnosis.  
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